No Data
No Data
Biora Therapeutics Reports Positive Data For Trial Of BT-600 In Ulcerative Colitis
Express News | Biora Therapeutics Inc: BT-600 Was Well Tolerated and Met All Trial Objectives
Express News | Biora Therapeutics Announces Positive Clinical Trial Results for BT-600
Express News | Biora Therapeutics-Entered Into Equity Distribution Agreement, Co May Offer & Sell From Time to Time up to $90 Mln of Shares of Co’s Common Stock
12 Health Care Stocks Moving In Monday's After-Market Session
GainersASLAN Pharma (NASDAQ:ASLN) shares moved upwards by 11.9% to $0.4 during Monday's after-market session. The market value of their outstanding shares is at $9.1 million. Biora Therapeutics (NASDA
Express News | Biora Therapeutics:Staff Notified Co That Its Securities Were Subject to Delisting From Nasdaq Unless Company Timely Requests Hearing Before Panel
No Data